HC Wainwright started coverage on shares of Lipocine Inc. (NASDAQ:LPCN) in a research report released on Friday. The firm issued a buy rating and a $25.00 target price on the specialty pharmaceutical company’s stock.
Separately, Canaccord Genuity reiterated a buy rating and issued a $6.00 target price on shares of Lipocine in a research report on Wednesday, August 10th.
Lipocine (NASDAQ:LPCN) opened at 4.60 on Friday. Lipocine has a one year low of $2.51 and a one year high of $14.80. The firm’s market cap is $83.99 million. The firm has a 50-day moving average of $3.90 and a 200-day moving average of $6.41.
Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. Analysts anticipate that Lipocine will post ($1.31) EPS for the current year.
A number of large investors have recently added to or reduced their stakes in LPCN. Dimensional Fund Advisors LP increased its stake in Lipocine by 1.5% in the second quarter. Dimensional Fund Advisors LP now owns 296,302 shares of the specialty pharmaceutical company’s stock worth $901,000 after buying an additional 4,464 shares during the last quarter. Royce & Associates LP increased its stake in Lipocine by 2.3% in the first quarter. Royce & Associates LP now owns 839,357 shares of the specialty pharmaceutical company’s stock worth $8,519,000 after buying an additional 19,134 shares during the last quarter. California State Teachers Retirement System bought a new stake in Lipocine during the second quarter worth about $106,000. Landscape Capital Management L.L.C. bought a new stake in Lipocine during the first quarter worth about $385,000. Finally, BlackRock Investment Management LLC increased its stake in Lipocine by 2,370.7% in the second quarter. BlackRock Investment Management LLC now owns 62,707 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 60,169 shares during the last quarter. Institutional investors own 47.23% of the company’s stock.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.